---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Dietary measures and parenteral glucose or glucagon"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Dietary measures and parenteral glucose or glucagon. Topics: Diet, glucose infusion, glucose monitoring, and glucagon for insulinoma: ENETS guidance; Dietary measures, tube feeding, and intravenous glucose for insulinoma: clinical review; Glucagon contraindication in insulinoma and other label limits: glucagon prescribing information; Continuous glucagon infusion for insulinoma and NICTH with liver metastases; 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/dietary-measures-and-parenteral-glucose-or-glucagon"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Dietary measures and parenteral glucose or glucagon

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Dietary Measures and Parenteral Glucose or Glucagon

<a id="topic-2.2.2.1.3-1"></a>

### Diet, glucose infusion, glucose monitoring, and glucagon for insulinoma: ENETS guidance

> “In the control of insulinoma-related hypoglycaemia, fractioned diet including complex carbohydrates with slow absorption is the cornerstone to avoid prolonged fasting [5, A]. Simple carbohydrates as well as glucose infusion are required in hypoglycaemic events.”
> “A CGMS could be a very useful tool in patients with insulinoma to early recognise a hypoglycaemic event and prevent severe complications. Furthermore, it is also possible to connect an infusion pump automatically administering glucose as required.”
> “To manage acute episodes of hypoglycaemia, glucagon therapy is now available in different formulations (intramuscular, subcutaneous, intranasal). The intranasal spray formulation is easily administered and rapidly effective in patients with severe hypoglycaemic events, especially when an intravenous glucose infusion is not available”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.3-2"></a>

### Dietary measures, tube feeding, and intravenous glucose for insulinoma: clinical review

> “Dietary/glucose: regular meals or snacks rich in slow carbohydrates, also ante noctem, are generally recommended (Fig. 3). The inclusion of a bedtime or late night meal is sufficient in most patients, but nocturnal tube feeding might be required to avoid nocturnal hypoglycemia in severely symptomatic patients. IV glucose administered via a central IV indwelling catheter might be needed for the control of severe recurrent hypoglycemia.”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.3-3"></a>

### Glucagon contraindication in insulinoma and other label limits: glucagon prescribing information

> “GVOKE is indicated for subcutaneous use for the treatment of severe hypoglycemia in adult and pediatric patients aged 2 years and older with diabetes.”
> “Insulinoma because of the risk of hypoglycemia [see Warnings and Precautions (5.2)]”
> “In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, glucagon administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GVOKE and GVOKE VialDx are contraindicated in patients with insulinoma [see Contraindications (4)].”
> “Patients with insufficient hepatic stores of glycogen may not respond to GVOKE for the treatment of severe hypoglycemia [see Clinical Pharmacology (12.2)]. Insufficient hepatic stores of glycogen may be present in conditions such as states of starvation, or in patients with adrenal insufficiency or chronic hypoglycemia.”
> “GVOKE and GVOKE VialDx are not approved for continuous infusion.”

Source: [Gvoke prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212097s012lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

### Continuous glucagon infusion for insulinoma and NICTH with liver metastases

> “Three patients had an insulinoma and four had non-islet cell tumor hypoglycemia (NICTH) due to hepatocellular carcinoma, colon carcinoma, meningeal sarcoma, and hemangiopericytoma, respectively. All of the patients had liver metastases.”
> “All patients with insulinoma responded to glucagon with a rise in blood serum glucose levels, indicating adequate glycogen stores. The four patients with NICTH had mixed responses: in two patients, the response suggested that hypoglycemia was due to an insulin-like tumor product; glucose levels did not rise in the other two cases, indicating that hypoglycemia was due to poor hepatic glycogen reserve/liver failure. In all cases, a glycemic response to glucagon predicted good response to long term treatment with glucagon (0.06-0.3 mg/hour, via intravenous infusion pump).”

Source: [Hoff and Vassilopoulou-Sellin (1998)](https://pubmed.ncbi.nlm.nih.gov/9554538/)

<a id="topic-2.2.2.1.3-5"></a>

### Glucose, nutrition, and glucagon infusion for NICTH: clinical review

> “Initial treatment of hypoglycemia is accomplished by oral glucose and/or iv glucose- or dextrose-containing fluids as necessary. In many cases, this suffices to avoid further hypoglycemia (47, 55, 61, 62).”
> “However, when prompt resection is not feasible, iv glucose or dextrose often does not suffice to prevent hypoglycemia.”
> “Continuous glucagon infusion can be successful if the patient has a positive response to a glucagon stimulation test, and parenteral nutrition may allow higher glucose delivery, but both are limited by the need for continuous iv infusion.”
> “However, the use of partial parenteral nutrition or total parenteral nutrition is not a desirable long-term strategy given the necessity of long-term venous access with its inherent risks of complications and concomitant risks of bloodstream infections, liver toxicity, and electrolyte imbalances, not to mention cost (84).”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
